Search

Your search keyword '"Martínez-Marín, Virginia"' showing total 41 results
Start Over Author "Martínez-Marín, Virginia"
41 results on '"Martínez-Marín, Virginia"'

1. Beyond cancer treatment: dermo-aesthetic and other wellness recommendations for breast cancer patients

Author

Falcón González, Alejandro, Gallegos Sancho, María Isabel, González Flores, Encarnación, Galve Calvo, Elena, Ruiz Vozmediano, Julia, Domingo García, Paloma, López Martos, Ricardo, Sánchez Rivas, Elena, Iglesias Urraca, Carmen María, Gómez Calvo, Ana Isabel, De Mariscal Polo, Amaia, Ramos-Medina, Rocío, Rivero, Maria, and Martínez Marín, Virginia

Published
2024
Full Text
View/download PDF

2. Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management

Author

Rosas-Alonso, Rocío, Colmenarejo-Fernández, Julian, Pernía, Olga, Burdiel, Miranda, Rodríguez-Antolín, Carlos, Losantos-García, Itsaso, Rubio, Tania, Moreno-Velasco, Rocío, Esteban-Rodríguez, Isabel, Martínez-Marín, Virginia, Yubero, Paloma, Costa-Fraga, Nicolas, Díaz-Lagares, Angel, López-López, Rafael, Díaz-Martin, Eva, García, Juan F., Sánchez, Catalina Vivancos, Gandía-González, Maria Luisa, Moreno-Bueno, Gema, de Castro, Javier, and de Cáceres, Inmaculada Ibánez

Published
2024
Full Text
View/download PDF

4. MiR-151a: a robust endogenous control for normalizing small extracellular vesicle cargo in human cancer

Author

Burdiel, Miranda, Jiménez, Julia, Rodríguez-Antolín, Carlos, García-Guede, Álvaro, Pernía, Olga, Sastre-Perona, Ana, Rosas-Alonso, Rocío, Colmenarejo, Julián, Rodríguez-Jiménez, Carmen, Diestro, María Dolores, Martínez-Marín, Virginia, Higueras, Oliver, Cruz, Patricia, Losantos-García, Itsaso, Peinado, Héctor, Vera, Olga, de Castro, Javier, and Ibáñez de Cáceres, Inmaculada

Published
2023
Full Text
View/download PDF

5. Tratamiento percutáneo del cáncer infiltrante de mama en estado clínico I/II mediante crioablación en pacientes sin indicación de cirugía axilar

Author

Oliver Goldaracena, José Maria, Cordoba Chicote, Vicenta, Roca Navarro, Maria Jose, Marti Alvarez, Covadonga, Garrido Alonso, Diego, Navarro Monforte, Ylenia, Diaz De Bustamante, Teresa, Garcia Martinez, Fernando, Yebenes, Laura, York Pineda, Elisa, Martinez Marin, Virginia, Zamora Auñon, Pilar, and Sanchez Mendez, Jose Ignacio

Published
2023
Full Text
View/download PDF

7. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations

Author

Marín, Francisco, López-Sendón, José Luis, Zamorano, José Luis, López-Fernández, Teresa, Martín-García, Ana, Roldán Rabadán, Inmaculada, Mitroi, Cristina, Mazón Ramos, Pilar, Díez-Villanueva, Pablo, Escobar Cervantes, Carlos, Alonso Martín, Concepción, Alonso Salinas, Gonzalo Luis, Arenas, Meritxell, Arrarte Esteban, Vicente Ignacio, Ayala de La Peña, Francisco, Castro Fernández, Antonio, García Pardo, Héctor, García-Sanz, Ramón, González Porras, José Ramón, López de Sá, Esteban, Lozano, Teresa, Marco Vera, Pascual, Martínez Marín, Virginia, Mesa Rubio, Dolores, Montero, Ángel, Oristrell, Gerard, Pérez de Prado, Armando, Velasco del Castillo, Sonia, Virizuela Echaburu, Juan Antonio, Zatarain-Nicolás, Eduardo, Anguita Sánchez, Manuel, and Tamargo Menéndez, Juan

Published
2019
Full Text
View/download PDF

8. Abordaje de la fibrilación auricular en pacientes con cáncer activo. Documento de consenso de expertos y recomendaciones

Author

Marín, Francisco, López-Sendón, José Luis, Zamorano, José Luis, López-Fernández, Teresa, Martín-García, Ana, Roldán Rabadán, Inmaculada, Mitroi, Cristina, Mazón Ramos, Pilar, Díez-Villanueva, Pablo, Escobar Cervantes, Carlos, Alonso Martín, Concepción, Alonso Salinas, Gonzalo Luis, Arenas, Meritxell, Arrarte Esteban, Vicente Ignacio, Ayala de La Peña, Francisco, Castro Fernández, Antonio, García Pardo, Héctor, García-Sanz, Ramón, González Porras, José Ramón, López de Sá, Esteban, Lozano, Teresa, Marco Vera, Pascual, Martínez Marín, Virginia, Mesa Rubio, Dolores, Montero, Ángel, Oristrell, Gerard, Pérez de Prado, Armando, Velasco del Castillo, Sonia, Virizuela Echaburu, Juan Antonio, Zatarain-Nicolás, Eduardo, Anguita Sánchez, Manuel, and Tamargo Menéndez, Juan

Published
2019
Full Text
View/download PDF

11. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

Author

Muñoz, Andrés, primary, Ay, Cihan, additional, Grilz, Ella, additional, López, Sonia, additional, Font, Carme, additional, Pachón, Vanesa, additional, Castellón, Victoria, additional, Martínez-Marín, Virginia, additional, Salgado, Mercedes, additional, Martínez, Eva, additional, Calzas, Julia, additional, Ortega, Laura, additional, Rupérez, Ana, additional, Salas, Eduardo, additional, Pabinger, Ingrid, additional, and Soria, Jose Manuel, additional

Published
2023
Full Text
View/download PDF

12. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients

Author

Cruzado Rodríguez, Juan Antonio, López Santiago, Sonia, Martínez Marín, Virginia, José Moreno, Gema, Custodio, Ana Belén, Feliu, Jaime, Cruzado Rodríguez, Juan Antonio, López Santiago, Sonia, Martínez Marín, Virginia, José Moreno, Gema, Custodio, Ana Belén, and Feliu, Jaime

Abstract

BACKGROUND: Chemotherapy can induce cognitive impairment in cancer patients. The main goal of this longitudinal study was to determine the incidence, characteristics, and duration of cognitive dysfunction in patients treated with adjuvant chemotherapy for colon cancer. PATIENTS AND METHODS: We assessed cognitive function, quality of life, anxiety and depression, fatigue, and hemoglobin levels in colon cancer patients at three assessment points: pre-chemotherapy (n=81), post-chemotherapy (n=73), and after 6-month follow-up (n=54). All patients were treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) for 6 months. RESULTS: Thirty patients (37%) had cognitive impairment in the pre-chemotherapy evaluation, mainly in processing speed and psychomotor executive function (Trail Making Test A and B). At the end of treatment, the main domain affected was the verbal memory, with an acute decline detected in 56% of patients. Fifty-four percent of the patients improved their dysfunction after 6 months of follow-up, whereas 18 (33%) of them showed worsening in at least one test. Cognitive impairment was most common in older patients and in those with less years of education. Quality of life, anxiety, depression, fatigue, and hemoglobin did not influence the results of the cognitive tests. CONCLUSIONS: Adjuvant FOLFOX4 in patients with colon cancer can have a negative effect on verbal memory. This deterioration is usually mild and transient., Depto. de Psicología Social, del Trabajo y Diferencial, Fac. de Psicología, TRUE, pub

Published
2023

14. 2023 GEIS Guidelines for gastrointestinal stromal tumors

Author

Serrano, César, primary, Martín-Broto, Javier, additional, Asencio-Pascual, José Manuel, additional, López-Guerrero, José Antonio, additional, Rubió-Casadevall, Jordi, additional, Bagué, Silvia, additional, García-del-Muro, Xavier, additional, Fernández-Hernández, Juan Ángel, additional, Herrero, Luís, additional, López-Pousa, Antonio, additional, Poveda, Andrés, additional, and Martínez-Marín, Virginia, additional

Published
2023
Full Text
View/download PDF

16. Symptom Clusters in Advanced Cancer

Author

Jiménez, Ana, Madero, Rosario, Alonso, Alberto, Martínez-Marín, Virginia, Vilches, Yolanda, Martínez, Beatriz, Feliu, Marta, Díaz, Leyre, Espinosa, Enrique, and Feliu, Jaime

Published
2011
Full Text
View/download PDF

19. When coronavirus is suspected

Author

Martín-Broto, Javier and Martínez Marín, Virginia

Abstract

According to recent guidelines for clinical practice published about the management of sarcoma during the coronavirus disease-2019 (COVID-19) pandemic, patients with a suspected infection should be screened for the presence of the virus. If confirmed or strongly suspected (clinically or by computed tomography [CT] scan), any cancer treatment must be postponed for at least 15 days after the start of symptoms and until the patient has recovered1. We present three clinical cases of patients with suspected COVID-19 in different situations.

Published
2021

20. Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients

Author

Instituto de Salud Carlos III, European Commission, Rosas, Rocio, Colmenarejo-Fernández, Julián, Pernía, Olga, Rodriguez-Antolín, Carlos, Esteban Rodriguez, Isabel, Ghanem, Ismael, Sanchez-Cabrero, Darío, Losantos-García, Itsaso, Palacios-Zambrano, Sara, Moreno-Bueno, Gema, Castro Carpeño, Javier de, Martínez-Marín, Virginia, Ibáñez de Cáceres, Inmaculada, Instituto de Salud Carlos III, European Commission, Rosas, Rocio, Colmenarejo-Fernández, Julián, Pernía, Olga, Rodriguez-Antolín, Carlos, Esteban Rodriguez, Isabel, Ghanem, Ismael, Sanchez-Cabrero, Darío, Losantos-García, Itsaso, Palacios-Zambrano, Sara, Moreno-Bueno, Gema, Castro Carpeño, Javier de, Martínez-Marín, Virginia, and Ibáñez de Cáceres, Inmaculada

Abstract

[Background]: The promoter hypermethylation of the methylguanine-DNA methyltransferase gene is a frequently used biomarker in daily clinical practice as it is associated with a favorable prognosis in glioblastoma patients treated with temozolamide. Due to the absence of adequately standardized techniques, international harmonization of the MGMT methylation biomarker is still an unmet clinical need for the diagnosis and treatment of glioblastoma patients. [Results]: In this study we carried out a clinical validation of a quantitative assay for MGMT methylation detection by comparing a novel quantitative MSP using double-probe (dp_qMSP) with the conventional MSP in 100 FFPE glioblastoma samples. We performed both technologies and established the best cutoff for the identification of positive-methylated samples using the quantitative data obtained from dp_qMSP. Kaplan–Meier curves and ROC time dependent curves were employed for the comparison of both methodologies. [Conclusions]: We obtained similar results using both assays in the same cohort of patients, in terms of progression free survival and overall survival according to Kaplan–Meier curves. In addition, the results of ROC(t) curves showed that dp_qMSP increases the area under curve time-dependent in comparison with MSP for predicting progression free survival and overall survival over time. We concluded that dp_qMSP is an alternative methodology compatible with the results obtained with the conventional MSP. Our assay will improve the therapeutic management of glioblastoma patients, being a more sensitive and competitive alternative methodology that ensures the standardization of the MGMT-biomarker making it reliable and suitable for clinical use.

Published
2021

21. Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas

Author

Ministerio de Economía y Competitividad (España), Universidad Autónoma de Madrid, Fundación Científica Asociación Española Contra el Cáncer, Escoll, Maribel, Lastra, Diego, Pajares, Marta, Robledinos-Antón, Natalia, Rojo, Ana I., Fernández-Ginés, Raquel, Mendiola, Marta, Martínez-Marín, Virginia, Esteban Rodriguez, Isabel, López-Larrubia, Pilar, Gargini, Ricardo, Cuadrado, Antonio, Ministerio de Economía y Competitividad (España), Universidad Autónoma de Madrid, Fundación Científica Asociación Española Contra el Cáncer, Escoll, Maribel, Lastra, Diego, Pajares, Marta, Robledinos-Antón, Natalia, Rojo, Ana I., Fernández-Ginés, Raquel, Mendiola, Marta, Martínez-Marín, Virginia, Esteban Rodriguez, Isabel, López-Larrubia, Pilar, Gargini, Ricardo, and Cuadrado, Antonio

Abstract

Transcription factor NRF2 orchestrates a cellular defense against oxidative stress and, so far, has been involved in tumor progression by providing a metabolic adaptation to tumorigenic demands and resistance to chemotherapeutics. In this study, we discover that NRF2 also propels tumorigenesis in gliomas and glioblastomas by inducing the expression of the transcriptional co-activator TAZ, a protein of the Hippo signaling pathway that promotes tumor growth. The expression of the genes encoding NRF2 (NFE2L2) and TAZ (WWTR1) showed a positive correlation in 721 gliomas from The Cancer Genome Atlas database. Moreover, NRF2 and TAZ protein levels also correlated in immunohistochemical tissue arrays of glioblastomas. Genetic knock-down of NRF2 decreased, while NRF2 overexpression or chemical activation with sulforaphane, increased TAZ transcript and protein levels. Mechanistically, we identified several NRF2-regulated functional enhancers in the regulatory region of WWTR1. The relevance of the new NRF2/TAZ axis in tumorigenesis was demonstrated in subcutaneous and intracranial grafts. Thus, intracranial inoculation of NRF2-depleted glioma stem cells did not develop tumors as determined by magnetic resonance imaging. Forced TAZ overexpression partly rescued both stem cell growth in neurospheres and tumorigenicity. Hence, NRF2 not only enables tumor cells to be competent to proliferate but it also propels tumorigenesis by activating the TAZ-mediated Hippo transcriptional program.

Published
2020

24. Primary ovarian Burkitt lymphoma

Author

Muñoz Martín, Andrés J., Pérez Fernández, Ricardo, Viñuela Beneítez, M. Carmen, Martínez Marín, Virginia, Márquez-Rodas, Iván, Sabin Domínguez, Pilar, and García Alfonso, Pilar

Published
2008
Full Text
View/download PDF

26. Abordaje de la fibrilación auricular en pacientes con cáncer activo. Documento de consenso de expertos y recomendaciones

Author

López-Fernández, Teresa, primary, Martín-García, Ana, additional, Roldán Rabadán, Inmaculada, additional, Mitroi, Cristina, additional, Mazón Ramos, Pilar, additional, Díez-Villanueva, Pablo, additional, Escobar Cervantes, Carlos, additional, Alonso Martín, Concepción, additional, Alonso Salinas, Gonzalo Luis, additional, Arenas, Meritxell, additional, Arrarte Esteban, Vicente Ignacio, additional, Ayala de La Peña, Francisco, additional, Castro Fernández, Antonio, additional, García Pardo, Héctor, additional, García-Sanz, Ramón, additional, González Porras, José Ramón, additional, López de Sá, Esteban, additional, Lozano, Teresa, additional, Marco Vera, Pascual, additional, Martínez Marín, Virginia, additional, Mesa Rubio, Dolores, additional, Montero, Ángel, additional, Oristrell, Gerard, additional, Pérez de Prado, Armando, additional, Velasco del Castillo, Sonia, additional, Virizuela Echaburu, Juan Antonio, additional, Zatarain-Nicolás, Eduardo, additional, Anguita Sánchez, Manuel, additional, Tamargo Menéndez, Juan, additional, Marín, Francisco, additional, López-Sendón, José Luis, additional, and Zamorano, José Luis, additional

Published
2019
Full Text
View/download PDF

27. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations

Author

López-Fernández, Teresa, primary, Martín-García, Ana, additional, Roldán Rabadán, Inmaculada, additional, Mitroi, Cristina, additional, Mazón Ramos, Pilar, additional, Díez-Villanueva, Pablo, additional, Escobar Cervantes, Carlos, additional, Alonso Martín, Concepción, additional, Alonso Salinas, Gonzalo Luis, additional, Arenas, Meritxell, additional, Arrarte Esteban, Vicente Ignacio, additional, Ayala de La Peña, Francisco, additional, Castro Fernández, Antonio, additional, García Pardo, Héctor, additional, García-Sanz, Ramón, additional, González Porras, José Ramón, additional, López de Sá, Esteban, additional, Lozano, Teresa, additional, Marco Vera, Pascual, additional, Martínez Marín, Virginia, additional, Mesa Rubio, Dolores, additional, Montero, Ángel, additional, Oristrell, Gerard, additional, Pérez de Prado, Armando, additional, Velasco del Castillo, Sonia, additional, Virizuela Echaburu, Juan Antonio, additional, Zatarain-Nicolás, Eduardo, additional, Anguita Sánchez, Manuel, additional, Tamargo Menéndez, Juan, additional, Marín, Francisco, additional, López-Sendón, José Luis, additional, and Zamorano, José Luis, additional

Published
2019
Full Text
View/download PDF

28. INCIDENCE OF THROMBOEMBOLIC DISEASE IN A COHORT OF PATIENTS WITH SARCOMA

Author

Font, Carme, primary, Ortega Morán, Laura, primary, Martínez Marín, Virginia, primary, Rodríguez, Adela, primary, Pachon Olmos, Vanessa, primary, Ruperez, Ana, primary, Salvador, Carmen, primary, Gutiérrez Sainz, Laura, primary, FOX, BARBARA, primary, de Toro Carmena, María, primary, and Muñoz Martín, Andrés, primary

Published
2019
Full Text
View/download PDF

29. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib

Author

Serrano, César, primary, García-del-Muro, Xavier, additional, Valverde, Claudia, additional, Sebio, Ana, additional, Durán, José, additional, Manzano, Aránzazu, additional, Pajares, Isabel, additional, Hindi, Nadia, additional, Landolfi, Stefania, additional, Jiménez, Laura, additional, Rubió-Casadevall, Jordi, additional, Estival, Anna, additional, Lavernia, Javier, additional, Safont, María José, additional, Pericay, Carles, additional, Díaz-Beveridge, Roberto, additional, Martínez-Marín, Virginia, additional, Vicente-Baz, David, additional, Vivancos, Ana, additional, Hernández-Losa, Javier, additional, Arribas, Joaquín, additional, and Carles, Joan, additional

Published
2018
Full Text
View/download PDF

30. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

Author

Zugazagoitia, Jon, primary, Biosca, Mercedes, additional, Oliveira, Julio, additional, Olmedo, María Eugenia, additional, Dómine, Manuel, additional, Nadal, Ernest, additional, Ruffinelli, José Carlos, additional, Muñoz, Nerea, additional, Luna, Ana María, additional, Hernández, Berta, additional, Martínez, Maite, additional, Gallego, Iria, additional, Martínez de Castro, Eva, additional, Font, Carme, additional, Calvo, Virginia, additional, Martínez-Marín, Virginia, additional, Corral, Jesús, additional, Noguerón, Esther, additional, Mondéjar, Rebeca, additional, García Escobar, Ignacio, additional, Salvador-Coloma, Carmen, additional, Juan, Óscar, additional, Sánchez Cánovas, Manuel, additional, Valdivia, Javier, additional, Ochoa, M. Pilar, additional, López Castro, Rafael, additional, Obispo, Berta, additional, Pangua, Cristina, additional, Sereno, María, additional, Fernández Franco, Lourdes, additional, Mielgo, Xabier, additional, Calzas, Julia, additional, Blasco, Ana, additional, Aparisi, Francisco, additional, Chara, Luis, additional, Grau, Juan Francisco, additional, Soares, Marta, additional, Gómez, Ana, additional, Zenzola, Victor, additional, García-Morillo, Marcial, additional, Cacho, Diego, additional, Díaz-Serrano, Asunción, additional, Aguado, Carlos, additional, Ponce-Aix, Santiago, additional, González-Larriba, Jose Luis, additional, Muñoz, Andrés J., additional, Lora, David, additional, Paz-Ares, Luis, additional, and Manzano, Aránzazu, additional

Published
2018
Full Text
View/download PDF

31. Predicción de la respuesta al tratamiento con Paclitaxel semanal y Bevacizumab en mujeres con cáncer de mama diseminado a través de un perfil de expresión génica

Author

Martínez Marín, Virginia, Redondo Sánchez, Andrés, Mendiola Sabio, Marta, UAM. Departamento de Medicina, Hospital Universitario La Paz, Servicio de Genómica del Parque Científico de Madrid, and Instituto Madrileño de Estudios Avanzados en Alimentación (IMDEA-Alimentación)

Subjects
Medicina, Mamas - Cáncer - Tratamiento - Tesis doctorales
Abstract

Tesis doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Medicina. Fecha de lectura: 18-12-2015, Esta tesis ha sido financiada por el Ministerio de Sanidad (proyecto EC 10-342) y el laboratorio Roche-Farma

Published
2015

32. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.

Author

Serrano, César, García‐del‐Muro, Xavier, Valverde, Claudia, Sebio, Ana, Durán, José, Manzano, Aránzazu, Pajares, Isabel, Hindi, Nadia, Landolfi, Stefania, Jiménez, Laura, Rubió‐Casadevall, Jordi, Estival, Anna, Lavernia, Javier, Safont, María José, Pericay, Carles, Díaz‐Beveridge, Roberto, Martínez‐Marín, Virginia, Vicente‐Baz, David, Vivancos, Ana, and Hernández‐Losa, Javier

Subjects
GASTROINTESTINAL tumors, CYTOGENETICS, SARCOMA, DRUG side effects, SYMPTOMS, TREATMENT effectiveness, TREATMENT duration, CANCER patients, METASTASIS, CONNECTIVE tissue tumors, LONGITUDINAL method, IMATINIB, GENETIC mutation, DISEASE progression
Abstract

Background: Oncogenic KIT/PDGFRA signaling inhibition with imatinib achieves disease control in most patients with advanced/metastatic gastrointestinal stromal tumor (GIST), but resistance eventually develops after 20–24 months. Notably, a small subset of these patients obtain durable benefit from imatinib therapy. Methods: We analyzed clinical, pathological, and molecular characteristics and long‐term outcomes in patients with metastatic GIST treated with continuous daily dosing of frontline imatinib in a cohort of patients benefiting for ≥5 years. A control group was obtained from the national Spanish Group for Sarcoma Research database and used as comparator. Results: Sixty‐four imatinib long‐term responders (LTRs) and 70 control cases were identified. Compared with controls, LTRs at baseline had better performance status (PS) 0–1 (100% vs. 81%), lower mitotic count (median, 8 vs. 15), and tumor burden (number of metastases, 3 vs. 7). KIT exon 11 was the only region found mutated in LTRs. LTRs achieved 34% complete responses and a median progression‐free survival of 11 years, compared with 4% and 2 years, respectively, in the control cohort. Prognostic factors that independently predicted long‐term benefit with imatinib were PS, number of metastases prior to imatinib, and response to imatinib. Fifteen LTR patients developed new side effects attributable to imatinib after ≥5 years of continuous treatment. No resistance mutations were found in metastatic samples from three patients progressing on imatinib. Conclusion: GISTs in LTRs are a distinctive entity with less aggressive behavior and marked sensitivity to KIT inhibition. Patients reaching 5 or more years on imatinib have a higher chance of remaining progression free over time. Implications for Practice: This work demonstrates that clinical and inherent tumor characteristics define a subset of patients with gastrointestinal stromal tumor (GIST) with increased likelihood to achieve durable response to first‐line imatinib therapy. Patients reaching ≥5 years on imatinib have a greater chance of remaining progression free over time, although the disease is unlikely to be cured. Imatinib is well tolerated for >5 years, and emergent toxicities are overall manageable. Resistance to imatinib emerging in patients with GISTs after long‐term imatinib treatment does not involve polyclonal expansion of KIT secondary mutations. This article identifies distinctive clinicopathological and molecular features in long‐term responders to imatinib treatment compared with patients with gastrointestinal stromal tumors reaching the usual median progression‐free survival. Clinical insights from this subgroup collected during the long‐term follow‐up are also provided. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

33. Predictive factors of early death after a comprehensive geriatric assessment in elderly cancer patients.

Author

Jimenez-Munarriz, Beatriz, primary, Madero, Rosario, additional, Jimenez Gordo, Ana M., additional, Molina-Garrido, MJ, additional, Saldana, Juana, additional, Girones, Regina, additional, De Castro, Javier, additional, Martínez-Marín, Virginia, additional, Cruz, Patricia, additional, Sanchez, Mar Munoz, additional, Rebollo, Maite Antonio, additional, Castelo, Beatriz, additional, Torres, Marisa, additional, Redondo, Andrés, additional, Martinez, Beatriz, additional, Custodio, Ana B., additional, Ghanem Canete, Ismael, additional, Bernal, Elsa, additional, and Feliu, Jaime, additional

Published
2015
Full Text
View/download PDF

34. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer (MBC) treated with bevacizumab and weekly paclitaxel (Bev-Pac).

Author

Redondo, Andrés, primary, Mendiola, Marta, additional, Martínez-Marín, Virginia, additional, Herranz, Jesus, additional, Yebenes, Laura, additional, Castelo, Beatriz, additional, Zamora, Pilar, additional, Pinto, Alvaro, additional, Cruz, Patricia, additional, Heredia, Victoria, additional, Diaz, Esther, additional, Gámez-Pozo, Angelo, additional, Fresno-Vara, Juan Angel, additional, Ramirez de Molina, Ana, additional, Hardisson, David, additional, and Espinosa, Enrique, additional

Published
2014
Full Text
View/download PDF

35. Biological bases of cognitive impairment induced by antinoeplastic treatment

Author

Feliu, Jaime, López-Santiago, Sonia, Martínez-Marín, Virginia, Custodio, Ana Belén, Cruzado, Juan Antonio, Feliu, Jaime, López-Santiago, Sonia, Martínez-Marín, Virginia, Custodio, Ana Belén, and Cruzado, Juan Antonio

Abstract

Often patients treated with chemotherapy and/or radiotherapy suffer memory and attention problems. The exact mechanisms of action are unknown, although several explanations have been proposed. Both chemotherapy and radiotherapy have a direct toxic effect in the CNS, especially neural progenitor cells and the glia, which are responsible for maintaining neurogenesis in the hippocampus and white matter integrity. Besides the treatments can induce vascular damage in the brain, altering the immune response mediated by cytokines, and hormonal changes secondary to either chemotherapy or hormone therapy itself. The intensity of these effects would be modulated by several genetic factors that influence the ability of neuronal repair, pharmacodynamics and activity of neurotransmitters., A menudo los pacientes que reciben tratamiento con quimioterapia y/o radioterapia presentan problemas de memoria y de atención. Se desconocen los mecanismos exactos por los que esto se produce, aunque se han propuesto diversas explicaciones. Tanto la quimioterapia como la radioterapia poseen una acción tóxica directa en el SNC, especialmente sobre las células progenitoras neurales y las de la glía, que son las responsables de mantener la neurogénesis del hipocampo y la integridad de la sustancia blanca. A ello cabe añadir el daño que pueden inducir los tratamientos en la vascularización cerebral, la alteración de la respuesta inmune mediada por citoquinas, y los cambios hormonales ya sean secundarios a la quimioterapia o a la propia hormonoterapia. La intensidad de estos efectos estaría modulada por diversos factores genéticos que influyen sobre la capacidad de reparación neuronal, la farmacodinamia y la actividad de los neurotransmisores.

Published
2012

39. Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast.

Author

Álvarez Criado, Javier, Zamora Auñon, Pilar, Martínez Marín, Virginia, GarcíaTrevijano Cabetas, Macarena, Collada Sánchez, Victoria Lucía, Espinosa Arranz, Enrique, Romero-Garrido, José Antonio, Benedi-González, Juana, Díaz Almirón, Mariana, and Herrero Ambrosio, Alicia

Subjects
*METASTATIC breast cancer, *PROTON pump inhibitors, *DRUG interactions, *PROTON-proton interactions, *TREATMENT duration
Abstract

The objective of this investigation was to assess the impact of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer (mBC) who received palbociclib as first-line or successives therapy.A retrospective observational study was conducted, enrolling patients diagnosed with estrogen receptor-positive, human epidermal growth factor receptor 2-negative mBC, and eligible for palbociclib treatment. Patients were categorized as “concurrent PPIs” if they received PPIs for at least two-thirds of the palbociclib therapy duration, and as “no concurrent PPIs” if they did not receive PPIs during the course of palbociclib treatment.A total of 165 patients were included in the study. Among first-line patients treated with palbociclib, those using concurrent PPIs exhibited a PFS of 8.88 months, while patients using palbociclib without concurrent PPIs had a PFS of 67.81 months (p < 0.0001). In second-line or subsequent treatments, patients on palbociclib with concurrent PPIs had a PFS of 7.46 months, whereas those using palbociclib without concurrent PPIs had a PFS of 17.29 months (p = 0.122).This study demonstrates that the concurrent use of PPIs in mBC patients receiving palbociclib negatively affects PFS, particularly in the first-line setting. Nevertheless, further investigation is warranted to explore the impact of PPIs on cycle-dependent kinase 4/6 inhibitors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Estudio volumétrico de adenomas hipofisarios no funcionantes: factores implicados en el grado de resección en cirugía endoscópica endonasal

Author

Pérez López, Carlos, Isla Guerrero, Alberto, Martínez Marín, Virginia, UAM. Departamento de Cirugía, Isla Guerrero, Alberto (dir.), and Martínez Marín, Virginia (dir.)

Subjects
Medicina, Adenomas hipofisarios - Tratamiento - Cirugía - Tesis doctorales
Abstract

Tesis doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Cirugía. Fecha de lectura: 18-03-2021

Published
2021

41. [Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].

Author

Martínez Marín V, Muñoz Martín AJ, Viñuela Benéitez MC, García Alfonso P, Alonso Muñoz A, and Pérez Manga G

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal administration & dosage, Breast pathology, Breast Neoplasms mortality, Breast Neoplasms pathology, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular pathology, Estradiol administration & dosage, Estradiol adverse effects, Estradiol therapeutic use, Estrogen Antagonists administration & dosage, Estrogen Antagonists adverse effects, Female, Follow-Up Studies, Fulvestrant, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Postmenopause, Retrospective Studies, Time Factors, Treatment Outcome, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms drug therapy, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Lobular drug therapy, Estradiol analogs & derivatives, Estrogen Antagonists therapeutic use
Abstract

Background and Objective: Fulvestrant (Flv) is a pure antiestrogen without agonist activity. Flv is effective as second line treatment in postmenopausal women with advanced breast cancer after tamoxifen., Material and Method: We performed a retrospective study of 36 consecutive postmenopausal women treated with Flv and advanced breast cancer progressing on prior therapies. 62,8% received Flv as third line treatment or more (all patients had previously received endocrine treatment for early or advanced breast cancer), 54,3% adjuvant chemotherapy and 67,5% received chemotherapy for metastatic disease. Our objective was to analyze the response rate, clinical benefit, time to progression (TTP) and toxicity profile., Results: In our study 11,4% patients had partial responses (PR) and 22,9% had a stable disease (SD) >24 weeks. Clinical benefit rate (CB) [RP+RC+SD]: 31,4%. TTP: 4,2 months (CI 95%, 2,6-5,8), with a median follow-up of 8,9 months. Flv was well tolerated, 22,9% patients had adverse events, all grade I/II, and only 5,7% of women gave up the treatment., Conclusions: These data demonstrate that Flv is an effective and safe therapy for heavily pre-treated postmenopausal women with advanced breast cancer.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results